Winner
Seizing the Moment for Indication Specific Pricing
by WA Communications on behalf of AbbVie, Alexion, Daiichi Sankyo, Gilead, Jazz Pharmaceuticals, J&J, Novartis, Pfizer, Sanofi
Summary of work
The Task and Finish Group on Indication Specific Pricing was created to drive impact on one of the most persistent challenges in medicines access; enabling better patient access to multi-indication medicines. With NHS England’s Commercial Framework consultation on the horizon, we saw a vital opportunity to drive long-overdue reform and ensure patients could access potentially life-saving and -enhancing treatments.
Powered by membership from nine solutions-focused pharmaceutical companies, we conducted deep analysis, created expert-led consensus and drove smart policy advocacy, leading to the first-ever cross-industry Joint Declaration on ISP. Our approach turned isolated industry efforts into one powerful, united voice, leading to a major policy shift.
From work cross sector to unify messaging and perspectives on ISP, to engaging ministers and trade bodies, our work shifted the dial. We turned ISP from a low-profile problem into a mainstream policy priority — unlocking clearer pricing pathways for new medicines and real hope for thousands of patients across England.
Judges’ comments
“Seizing the Moment for Indication Specific Pricing” was a really strong, solid programme with great outcomes. The judges recognised how difficult it is to pull coalitions together and this campaign did it very well with the nine companies involved. The strategy was laser focused and the fact that it managed to get a shift in government policy was really impressive.
